glp-1 parkinson's disease Are we measuring the wrong primary outcome for drugs for Parkinson's? Spoiler alert: the pooled data suggests we should pivot away from a motor outcome. Should we think cognitive, autonomic, sleep Gut neuropeptide involvement in Parkinson's

lncRNAs are increasingly acknowledged for their roles in several cancer-related signaling pathways, often displaying oncogenic or tumor-suppressive properties

As a result, clinicians now have Read More Counseling Patients on Emerging GLP-1 Benefits: How to Balance Evidence and Expectations Apr 27, 2026 Articles, Diabetes, GLP- 1 Agonist Therapy Center, GLP-1 Agonist Therapy Center, Type 2 Diabetes, Type 2 Diabetes 3,024 views Patients today are more informed than ever, but are they always getting the full picture

No, never change your anticoagulant or antiplatelet medication dosing or timing for injections

The increased risk for cancer associated with obesity is mediated partly by changes in the immune system

The New Phase of the GLP-1 Journey When GLP-1 injections first gained attention, the focus was on weight loss